

# BÖLÜM

# 11

## Tiroid Kanser Cerrahisinde Boyun Diseksiyonu

■ Prof. Dr. Mehmet Hakan KORKMAZ

### Özet

Diferansiye tiroid kanserlerinde boyun lenf nodlarına yüksek oranda bölgesel/rejyonel metastaz olur (%20-90). Bunların en az yarısı mikrometastazdır (<2mm), ve preoperatif olarak boyunda klinik olarak tespit edilebilmeleri mümkün olmadığından, gizli/okült metastaz olarak kabul edilirler. Başboyun bölgesi üst aerodigestif sistem skuamöz hücreli kanserlerinin aksine; tiroid kanserlerinde bölgesel okült metastaz, özellikle 55 yaş öncesinde, прогнозu olumsuz etkilemez. Klinik olarak N+ olan hastalarda tedavi edici boyun diseksiyonu endikasyonu vardır. N0 hastalarda profilaktif/elektif lateral (II,II,IV bölgeler) boyun diseksiyonu endikasyonu yoktur, santral bölge (VI.) ise çok tartışmalıdır. Santral bölgede %40 lara varan okült metastaz olmasına rağmen ATA-2015 rehberi 4 cm altındaki tümörlerde profilaktik santral boyun diseksiyonunu önermemektedir. Ancak diğer bir grup otör, deneyimli ellerde kalıcı rekürren sinir paralizisi (%0.5-1.4) ve hipokalseminin (%1-2) çok az olması nedeniyle rutin elektif santral bölge diseksiyonunu önermektedir. Her ne kadar bölgesel nüks oranı diseksiyon yapılanlarda %4, yapılmayanlarda %7 olsa da, fark istatiksel olarak anlamlı değildir.

Sonuç olarak klinik olarak N+ tüm hastalarda tedavi edici boyun diseksiyonu yapılmalıdır. N0 boyunlarda ise 4 cm altındaki papiller kanserlerde tartışmalı, folliküler kanserler de elektif santral diseksiyon endikasyonu yoktur. Medüller kanserlerde her zaman santral bölge profilaktif boyun diseksiyonu endikasyonu vardır; lateral bölge ise tartışmalıdır.

Profilaktik boyun diseksiyonları ise tartışımlıdır. Bu nedenle tiroid kanseri cerrahisi yapan hekimlerin boyun cerrahi anatomisine ve boyun diseksiyonları yöntemlerine hakim olması çok önemlidir. Doğru endikasyonla, doğru ameliyat ve tedavilerle iyi diferansiyel tiroid kanserlerinin

yüksek oranda ve çok düşük morbidite ile tedavi edilebileceği unutulmamalıdır. Bu nedenle yüksek volümlü ve deneyimli cerrahlar, gerek genel cerrahlar gerek KBB baş boyun cerrahları, tarafindan ameliyatların uygulanması önemlidir.

## Kaynaklar

1. Korkmaz H. Boyun Kitlelerine Yaklaşım. Önerci M-Korkmaz H, editörler. Kulak Burun Boğaz Baş Boyun Cerrahisi Hastalıkları-Baş Boyun Cerrahisi. 1. Baskı, Ankara: Güneş Tip Kitabevleri; 2018, s23-28.
2. Korkmaz H. Boyun Cerrahi Anatomisi. Önerci M-Korkmaz H, editörler. Kulak Burun Boğaz Baş Boyun Cerrahisi Hastalıkları-Baş Boyun Cerrahisi. 1. Baskı, Ankara: Güneş Tip Kitabevleri; 2018, s1-11.
3. Robins KT, Medina JE, Wolf GT, et. al. Standardizing neck dissection terminology: official report of the Academy's Committee for Head and Neck Surgery and Oncology. *Arch Otolaryngol Head neck Surg* 1991; 117(6): 601-605.
4. Robins KT, Shah AR, Medina JE, et. al. Consensus statement on the classification and terminology of neck dissection. *Arch Otolaryngol Head Neck Surg* 2008;134 (5): 536-538.
5. Spiro RH<sup>1</sup>, Strong EW, Shah JP. Classification of neck dissection: variations on a new theme. *Am J Surg* 1994 Nov;168(5):415-8.
6. Shah JP<sup>1</sup>, Andersen PE. The impact of patterns of nodal metastasis on modifications of neck dissection. *Ann Surg Oncol* 1994 Nov;1(6):521-32.
7. Sylvia L. Asa, MD, PhD. The Current Histologic Classification of Thyroid Cancer. *Endocrinol Metab Clin N Am* 2019; (48): 1-22.
8. Cooper DS, Doherty GM, Haugen BR, et al. American Thyroid Association Guidelines Taskforce on Thyroid nodules, Differentiated Thyroid cancer, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2009; 19(11):1167-1214.
9. Shi Y, Jin L, Zheng L. Partially cystic thyroid nodules on ultrasound: The associated factors for malignancy. *Clinical Hemorheology and Microcirculation* 2019; (91) 1-9.
10. Kyle A. Zanocco, Max M. Wang, et al. Selective use of Molecular Testing Based on Sonographic Features of Cytologically Indeterminate Thyroid Nodules: A Decision Analysis. *World Journal of Surgery* 2019; 26.
11. Ma Y, Qian F, Wang J, et al. Primary accessory thyroid carcinoma with negative 99m TcO 4 – SPECT/CT imaging: a case report and literature review. *Journal of International Medical Research* 2019; (47):8, 3934-3939.
12. Bongers PJ, Kluijfhout WP, Verzijl R, et al. Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease. *Annals of Surgical Oncology* 2019; (26):8, 2533-2539.
13. Yoon SJ, Na DG, Gwon HY, et al. Similarities and Differences Between Thyroid Imaging Reporting and Data Systems. *American Journal of Roentgenology* 2019; 213:2, 76-84.
14. Kouvaraki MA, Shapiro SE, Foranage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. *Surgery* 2003; 134(6):946-954.
15. Shen WT, Ogawa L, Ruan D, et al. Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations. *Arch Surg* 2010; 145(3):272-275.
16. Gay S, Monti E, Antonelli CT, et al. Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinoma. *Future Oncology* 2019; 15:(24); 13-19.
17. Porcelli T, Sessa F, Gambale C, et al. Management of one patient with oligoprogressive thyroid cancer during treatment with lenvatinib. *Future Oncology* 2019; 15:(24), 21-25.
18. Lan X, Sun W, Zhang H, et al. A meta-analysis of central lymph node metastasis for predicting lateral involvement in papillary thyroid carcinoma. *Otolaryngology Head Neck Surg* 2015; 153(5):731-8.
19. Park JH, Lee YS, Kim BW, et al. Skip lateral neck node metastases in papillary thyroid carcinoma. *World J Surg* 2012; 36(4):743-7.
20. Qubain SW, Nakano S, Baba M. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. *Surgery* 2002; 131:249- 256.
21. Wang TS, Cheung K, Farrokhyar F, et al. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. *Ann Surg Oncol* 2013; 20(11):3477-3483.
22. Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid* 2016; 26(1):1-133.
23. Hughes DT, White ML, Miller BS, et al. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. *Surgery* 2010; 148(6):1100-6.
24. Moo TA, McGill J, Allendorf J, et al. Management of one patient with oligoprogressive thyroid cancer during treatment with lenvatinib. *Future Oncology* 2019; 15:(24); 13-19.

- al. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. *World J Surg* 2010; 34(6):1187–1191.
25. Wang TS, Evans DB, Fareau GG, et al. Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer. *Ann Surg Oncol* 2012; 19(13):4217– 4222.
26. Chad M. Hall, MD, Samuel K, et al. Routine central lymph node dissection with total thyroidectomy for papillary thyroid cancer potentially minimizes level VI recurrence *Surgery* 2016 Oct;160(4):1049-1058.
27. Hanson MA, Shaha AR, Wu JX. Surgical approach to the substernal goiter. *Best Practice & Research Clinical Endocrinology & Metabolism* 2019; 33:4.
28. Hartl DM, Hadoux J, Guerlain J, et al. Risk-oriented concept of treatment for intrathyroid papillary thyroid cancer. *Best Practice & Research Clinical Endocrinology & Metabolism* 2019; 33:4.
29. Staubitz JI, Musholt PB, Musholt TJ. The surgical dilemma of primary surgery for follicular thyroid neoplasms. *Best Practice & Research Clinical Endocrinology & Metabolism* 2019; 33:4.
30. Xu B, Ghossein R. Critical Prognostic Parameters in the Anatomic Pathology Reporting of Differentiated Follicular Cell-Derived Thyroid Carcinoma. *Cancers* 2019; 11:8, 1100.
31. Aydemirli MD, Corver W, Beuk R, et al. Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hürthle Cell Cancer. *Cancers* 2019; 11:8, 1185.
32. Lee YK, Lee H, Han S, et al. Association between Thyroid-Stimulating Hormone Level after Total Thyroidectomy and Hypercholesterolemia in Female Patients with Differentiated Thyroid Cancer: A Retrospective Study. *Journal of Clinical Medicine* 2019; 8:8, 1106.
33. Marcin Barczyński, Małgorzata Stopa-Barczyńska. 2019. Hemithyroidectomy for benign euthyroid asymmetric nodular goitre. *Best Practice & Research Clinical Endocrinology & Metabolism* 33:4, 101288. [Crossref]
34. Li XJ, Mao XD, Chen GF, et al. High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules. *Medicine* 2019; 98:28, e16343.